NEW YORK, June 24, 2026, 14:04 EDT
- Kenvue was up 1.7% at $18.72 after Tuesday’s 3.1% gain.
- Kimberly-Clark’s offer was worth about $19.11 a Kenvue share at the latest KMB price.
- Regulatory approval and lawsuit risk remain the main swing factors.
Kenvue Inc. shares rose on Wednesday and added to the prior session’s gain, as the Tylenol and Band-Aid maker traded below the current value of Kimberly-Clark’s pending cash-and-stock takeover offer.
Kenvue recently traded at $18.72, up 1.7%, with volume of 32.6 million shares. Kimberly-Clark rose 2.7% to $106.71, and consumer-health peer Haleon gained 3.2%.
At Kimberly-Clark’s latest price, the offer — $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share — was worth about $19.11 a Kenvue share. The deal spread, the gap between Kenvue’s price and the value of the offer, was about 2%.
Kenvue closed Tuesday at $18.41, up 3.08%, while the S&P 500 fell 1.44% and the Dow slipped 0.09%, MarketWatch reported.
The latest company numbers gave the trade some support. In May, Kenvue reported first-quarter net sales up 4.5% and organic sales, which exclude currency moves and deal effects, up 0.7%. Diluted profit per share rose to 25 cents from 17 cents. Chief Executive Kirk Perry called the start of the year “encouraging,” but Kenvue did not give guidance, its own forecast, because of the pending Kimberly-Clark deal. Kenvue Investor Relations
RBC Capital Markets analyst Nik Modi said after the first-quarter report that the results were bullish for Kimberly-Clark as “Kenvue’s fundamentals seem to be stabilizing,” Reuters reported. Reuters
Kimberly-Clark and Kenvue shareholders approved the deal in January. The companies said the transaction was expected to close in the second half of 2026, subject to regulatory approvals and other standard closing conditions.
But the deal is not just a price exercise. Approval from regulators is still pending, the offer value moves with Kimberly-Clark stock, and lawsuit headlines around Tylenol can still hurt the spread. TD Cowen analyst Robert Moskow said Kimberly-Clark would take on potential Tylenol litigation risk and that the exposure “is hard to quantify,” Reuters reported. Reuters
